{"id":643908,"date":"2023-03-22T20:14:01","date_gmt":"2023-03-22T20:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=643908"},"modified":"2023-03-22T20:14:01","modified_gmt":"2023-03-22T20:14:01","slug":"triple-negative-breast-cancer-pipeline-assessment-2023-insight-into-the-current-therapies-emerging-drugs-treatment-outlook-and-key-companies-hibercell-roche-infinity-pharmaceuticals-cytodyn","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/triple-negative-breast-cancer-pipeline-assessment-2023-insight-into-the-current-therapies-emerging-drugs-treatment-outlook-and-key-companies-hibercell-roche-infinity-pharmaceuticals-cytodyn_643908.html","title":{"rendered":"Triple Negative Breast Cancer Pipeline Assessment 2023| Insight into the current therapies, emerging drugs, treatment, outlook, and key companies:  HiberCell, Roche, Infinity Pharmaceuticals, CytoDyn"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585718874.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Triple Negative Breast Cancer Pipeline Assessment 2023| Insight into the current therapies, emerging drugs, treatment, outlook, and key companies:  HiberCell, Roche, Infinity Pharmaceuticals, CytoDyn\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585718874.jpeg\" alt=\"Triple Negative Breast Cancer Pipeline Assessment 2023| Insight into the current therapies, emerging drugs, treatment, outlook, and key companies:  HiberCell, Roche, Infinity Pharmaceuticals, CytoDyn\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s Triple Negative Breast Cancer Pipeline 2022, covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Triple Negative Breast Cancer Pipeline 2022<\/a>,<\/strong> covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Takeaways from the Triple Negative Breast Cancer Pipeline Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Over 6 companies and 6+pipeline drugs in Triple Negative Breast Cancer are in various stages of development, and their anticipated acceptance in the Triple Negative Breast Cancer Pipeline market would significantly increase market revenue.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Triple Negative Breast Cancer Pipeline companies developing novel drug candidates to improve the Triple Negative Breast Cancer Pipeline treatment landscape include HiberCell, Roche, Infinity Pharmaceuticals, CytoDyn, and many others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Triple Negative Breast Cancer Pipeline therapies in various stages of development include Imprime PGG, Tecentriq, IPI-549 (Eganelisib), and many others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Triple Negative Breast Cancer Pipeline Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Triple Negative Breast Cancer Pipeline Insights, 2022&#8243; report by DelveInsight outlays comprehensive insights of the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer market. A detailed picture of the TNBC pipeline landscape is provided, which includes the disease overview and Triple Negative Breast Cancer treatment guidelines. The assessment part of the report embraces in-depth Triple Negative Breast Cancer commercial assessment and clinical assessment of the TNBCpipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Triple Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/fe6f1331eaf546825e112d48892153cb.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Triple Negative Breast Cancer Pipeline Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Imprime PGG: Hyber Cell&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Tecentriq: Roche&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Discover more about the emerging Triple Negative Breast Cancer Pipeline drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">TripleNegative Breast Cancer Pipeline Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Triple Negative Breast Cancer Pipeline Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Imprime PGG: Hiber Cell<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tecentriq: Hoffmann-La Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IPI-549 (Eganelisib): Infinity Pharmaceutical&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And many others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Triple Negative Breast Cancer Pipeline Pipeline Therapeutics Assessment- By Products, By Route of Administration, By Molecule Type.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Triple Negative Breast Cancer Pipeline Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Triple Negative Breast Cancer Pipeline Companies: HiberCell, Hoffman La Roche, Infinity Pharmaceuticals, and many others<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Triple Negative Breast Cancer Pipeline Pipeline Therapies: Imprime PGG, Tecentriq, IPI-549 (Eganelisib), Leronlimab (PRO 140) and many others<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Find out more about the Triple Negative Breast Cancer in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Triple Negative Breast Cancer Pipeline Clinical Trials<\/a><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Introduction of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Overview of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Pipeline Therapeutics of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Late-Stage Products (Phase III) of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Mid-Stage Products (Phase II) of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Early Stage Products (Phase I\/II) of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Preclinical Stage Products of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Discovery Stage Products of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Therapeutic Assessment of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Inactive Products of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Unmet Needs of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Market Drivers and Barriers of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix of Triple Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. <\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul <br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=triple-negative-breast-cancer-pipeline-assessment-2023-insight-into-the-current-therapies-emerging-drugs-treatment-outlook-and-key-companies-hibercell-roche-infinity-pharmaceuticals-cytodyn\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=triple-negative-breast-cancer-pipeline-assessment-2023-insight-into-the-current-therapies-emerging-drugs-treatment-outlook-and-key-companies-hibercell-roche-infinity-pharmaceuticals-cytodyn\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s Triple Negative Breast Cancer Pipeline 2022, covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/triple-negative-breast-cancer-pipeline-assessment-2023-insight-into-the-current-therapies-emerging-drugs-treatment-outlook-and-key-companies-hibercell-roche-infinity-pharmaceuticals-cytodyn_643908.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-643908","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/643908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=643908"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/643908\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=643908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=643908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=643908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}